Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers [0.03%]
隐藏在众目睽睽之下：非神经营养性受体酪氨酸激酶驱动的肺癌中酪氨酸激酶抑制的神经保护作用益处
D Ross Camidge,William J Phillips,Raphael A Nemenoff et al.
D Ross Camidge et al.
Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC [0.03%]
NSCLC中非V600 BRAF改变的生物学和临床管理
Sandra Ortiz-Cuaran,Laurine Dupriez,Constance Nicq et al.
Sandra Ortiz-Cuaran et al.
BRAF mutations are detected in approximately 3% to 8% of patients with NSCLC. In contrast to melanoma, in which most BRAF mutations occur at the V600 codon, only approximately 35% of BRAF-mutant NSCLC tumors harbor V600 mutations. Among the...
Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs [0.03%]
HER2突变型NSCLC对T-DXd耐药机制及其对后续使用HER2 TKIs敏感性的潜在影响：载荷灵敏度丧失等問題的考量
Monique B Nilsson,Xiuning Le,Alissa Poteete et al.
Monique B Nilsson et al.
Introduction: Effective therapies are needed for NSCLC patients with HER2 mutant tumors that progress on the HER2 antibody drug conjugate trastuzumab deruxtecan (T-DXd), a standard-of-care treatment. A greater understandi...
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trials [0.03%]
针对EGFR突变型肺癌脑转移患者的奥希替尼联合立体定向放射外科手术的STARLET分析：来自OUTRUN和LUO试验的随机对照研究联合分析结果
Chee Khoon Lee,Shilo Lefresne,Yu Yang Soon et al.
Chee Khoon Lee et al.
Introduction: Clinical guidelines recommend upfront osimertinib monotherapy for asymptomatic brain metastases (BM) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), despite a lack of ra...
Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer [0.03%]
肺癌患者放疗过程中心脏功能的改变规律及危险因素研究
Ivy S Han,Kyunga Ko,Jennifer Wei Zou et al.
Ivy S Han et al.
Introduction: The cardiovascular toxicity of radiation therapy (RT) remains incompletely understood in patients with non-small cell lung cancer (NSCLC). Our objective was to define changes in echocardiographic parameters ...
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact [0.03%]
胸部肿瘤基础科学的最新进展及其转化影响
Michele Carbone,Christopher Amos,Richard L Attanoos et al.
Michele Carbone et al.
In this article, we summarize the progress made in lung cancer, mesothelioma, and thymic epithelial malignancy during the period 2005-2025. We enlisted multidisciplinary thoracic oncologic experts to tackle this task. The main focus of the ...
20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies [0.03%]
二十年砥砺奋进之路：重塑胸部恶性肿瘤的诊疗格局
Fen Wang,Dipesh Uprety,Alex A Adjei
Fen Wang
The Immune Cost of the Thymus: Navigating Autoimmunity and Tumor Management in Thymic Epithelial Tumors [0.03%]
胸腺上皮肿瘤中的免疫成本：自身免疫和肿瘤管理的调控
Luca Bertolaccini,Claudia Bardoni,Monica Casiraghi et al.
Luca Bertolaccini et al.
Less Is More? Minimizing Overtreatment in Patients With Multifocal Ground-Glass Opacities [0.03%]
少即是多？减少对多灶性磨玻璃样不透明患者的过度治疗
Benedikt Niedermaier,Hauke Winter
Benedikt Niedermaier
Does the Dictum of Masterful Inactivity for Subsolid Nodules Also Apply for Multiple Ones? [0.03%]
对于多发亚实性结节是否也适用观察等待策略？
Pawan Kumar Singh,Puneet Saxena,Aman Ahuja
Pawan Kumar Singh